Using Relaxin-2 to Treat Frozen Shoulder
Sustained Release Relaxin-2 for the Treatment of Frozen Shoulder
['FUNDING_R01'] · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · NIH-11092216
This study is testing a new way to help people with frozen shoulder by using a hormone called relaxin-2 to ease pain and improve movement, and it could offer better long-lasting relief than the treatments currently available.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11092216 on ClinicalTrials.gov |
What this research studies
This research investigates a new treatment for frozen shoulder, a condition affecting millions of people. It focuses on using a hormone called relaxin-2, which helps soften tissues, to reduce the fibrous tissue buildup that causes pain and limited movement in the shoulder. The approach involves delivering relaxin-2 in a controlled manner using special biodegradable materials, aiming to provide long-lasting relief and improve shoulder function. Patients may benefit from a more effective treatment option compared to current therapies that only offer temporary relief.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults over 21 years old who are experiencing symptoms of frozen shoulder.
Not a fit: Patients with frozen shoulder who have already undergone surgical interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and long-lasting treatment for patients suffering from frozen shoulder.
How similar studies have performed: While the use of relaxin-2 for this specific condition is novel, similar approaches using peptide therapies have shown promise in other fibrotic conditions.
Where this research is happening
BOSTON, UNITED STATES
- BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRINSTAFF, MARK W. — BOSTON UNIVERSITY (CHARLES RIVER CAMPUS)
- Study coordinator: GRINSTAFF, MARK W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.